Apnimed(APMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APMD Apnimed

未开盘 09-30 16:00:00 EDT

21.91

-1.99

-8.33%

盘后22.30

+0.39+1.78%

19:30 EDT

最高24.50	最低21.49	成交量66.96万
今开23.57	昨收23.90	日振幅12.62%
总市值9.12亿	流通市值2.63亿	总股本4,163万
成交额1,488万	换手率5.58%	流通股本1,200万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"APMD","market":"US","secType":"STK","nameCN":"Apnimed","latestPrice":21.91,"timestamp":1790798400000,"preClose":23.9,"halted":0,"volume":669622,"hourTrading":{"tag":"盘后","latestPrice":22.3,"preClose":21.91,"latestTime":"19:30 EDT","volume":7236,"amount":158936.2005,"timestamp":1790811003443,"change":0.39,"changeRate":0.0178,"amplitude":0.018713},"delay":0,"changeRate":-0.08326359832635977,"floatShares":12000000,"shares":41630779,"eps":3.898,"marketStatus":"未开盘","change":-1.99,"latestTime":"09-30 16:00:00 EDT","open":23.57,"high":24.5,"low":21.485,"amount":14878180.55305,"amplitude":0.126151,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":3.898,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"listingDate":1785470400000,"exchange":"NASDAQ","adjPreClose":23.9,"preHourTrading":{"tag":"盘前","latestPrice":23.58,"preClose":23.9,"latestTime":"09:27 EDT","volume":2026,"amount":48107.475352,"timestamp":1790774860001,"change":-0.32,"changeRate":-0.013389,"amplitude":0.044791},"postHourTrading":{"tag":"盘后","latestPrice":22.3,"preClose":21.91,"latestTime":"19:30 EDT","volume":7236,"amount":158936.2005,"timestamp":1790811003443,"change":0.39,"changeRate":0.0178,"amplitude":0.018713},"volumeRatio":1.334287},"requestUrl":"/m/hq/s/APMD","defaultTab":"news","newsList":[{"id":"2656639897","title":"美股异动 | 睡眠呼吸暂停药物研发商Apnimed(APMD.US)登陆美股市场 开盘股价涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656639897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656639897?lang=zh_cn&edition=full","pubTime":"2026-08-01 00:08","pubTimestamp":1785514105,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["APMD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174858058","title":"异动解读 | Apnimed上市首日盘中大涨37.5%，IPO定价超预期引发市场追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1174858058","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174858058?lang=zh_cn&edition=full","pubTime":"2026-07-31 23:46","pubTimestamp":1785512792,"startTime":"0","endTime":"0","summary":"生物技术公司Apnimed今日盘中股价大涨37.5%，引发市场广泛关注。此前，Apnimed将IPO发行价定在每股16美元，超出14至16美元的初始定价区间上限，并将发行规模从原计划的1000万股扩大至1200万股，最终募资1.92亿美元。强劲的IPO定价和扩大的发行规模，反映出市场对其投资价值的高度认可，推动股价开盘后大幅走高，最新显示股价达到22美元，远超发行价。Apnimed总部位于马萨诸塞州剑桥市，是一家处于后期研发阶段的生物技术公司。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133013771","title":"Apnimed 公司IPO定价：1200万股普通股以每股16美元公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1133013771","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133013771?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:11","pubTimestamp":1785463869,"startTime":"0","endTime":"0","summary":"Apnimed公司宣布其首次公开募股（IPO）定价已确定。此次发行规模为1200万股普通股，每股定价为16美元，面向公众出售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654273030","title":"生物科技公司Apnimed冲刺美股：最高募资1.6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654273030","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654273030?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:37","pubTimestamp":1785206250,"startTime":"0","endTime":"0","summary":"美国生物科技公司Apnimed（股票代码：“APMD”）日前递交招股书，准备在美国纳斯达克上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260728/6392083182331291075080922.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260728/6392083182331291075080922.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34488/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["159837","APMD","MEDX","BK4588","LNGR","SYNB","BK4581","BK4585","AGNG","IEIH","IBBJ","XBI","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188583087","title":"Apnimed宣布FDA受理AD109新药申请，该口服研究性药物用于治疗成人阻塞性睡眠呼吸暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=1188583087","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188583087?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:01","pubTimestamp":1784030488,"startTime":"0","endTime":"0","summary":"Apnimed公司宣布，美国食品药品监督管理局（FDA）已正式受理其新药AD109的申请。AD109是一种研究性口服药物，旨在用于治疗成人阻塞性睡眠呼吸暂停（OSA）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121237357","title":"Apnimed旗下AD109在三期试验中总体耐受性良好，口干、失眠、恶心为常见不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1121237357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121237357?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:01","pubTimestamp":1784030487,"startTime":"0","endTime":"0","summary":"Apnimed Inc. 宣布，其候选药物AD109在关键性三期临床试验中展现出总体良好的耐受性。数据显示，治疗过程中报告的不良事件大多为轻度至中度。其中，口干、失眠和恶心是最为常见的副作用。这些发现对于评估该药物的整体安全性特征至关重要。公司表示，详细的数据将在未来的医学会议上进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apnimed.com","stockEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.1653},{"period":"3month","weight":0.3694},{"period":"ytd","weight":0.3694}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apnimed, Inc.于2017年6月根据特拉华州法律成立。该公司是一家后期临床制药公司，致力于发现、开发和商业化新型口服疗法，解决睡眠相关呼吸疾病的神经生物学问题。其唯一的临床候选产品Oxnimbi是一种研究性固定剂量抗呼吸暂停神经肌肉调节剂，结合新型抗毒蝇碱和选择性去甲肾上腺素再摄取抑制剂，旨在通过改善上气道肌肉活动来治疗阻塞性睡眠呼吸暂停，以维持气道通畅并防止睡眠期间气道塌陷，并于2026年4月向FDA提交了一份新药申请。","exchange":"NASDAQ","name":"Apnimed","nameEN":"Apnimed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apnimed(APMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apnimed(APMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apnimed,APMD,Apnimed股票,Apnimed股票老虎,Apnimed股票老虎国际,Apnimed行情,Apnimed股票行情,Apnimed股价,Apnimed股市,Apnimed股票价格,Apnimed股票交易,Apnimed股票购买,Apnimed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apnimed(APMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apnimed(APMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}